198 related articles for article (PubMed ID: 2893037)
1. Thrombolysis with tissue plasminogen activator in acute myocardial infarction: no additional benefit from immediate percutaneous coronary angioplasty.
Simoons ML; Arnold AE; Betriu A; de Bono DP; Col J; Dougherty FC; von Essen R; Lambertz H; Lubsen J; Meier B
Lancet; 1988 Jan; 1(8579):197-203. PubMed ID: 2893037
[TBL] [Abstract][Full Text] [Related]
2. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) phase II trial.
TIMI Study Group
N Engl J Med; 1989 Mar; 320(10):618-27. PubMed ID: 2563896
[TBL] [Abstract][Full Text] [Related]
3. Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.
Van de Werf F; Arnold AE
BMJ; 1988 Nov; 297(6660):1374-9. PubMed ID: 3146370
[TBL] [Abstract][Full Text] [Related]
4. A randomized trial comparing primary angioplasty with a strategy of short-acting thrombolysis and immediate planned rescue angioplasty in acute myocardial infarction: the PACT trial. PACT investigators. Plasminogen-activator Angioplasty Compatibility Trial.
Ross AM; Coyne KS; Reiner JS; Greenhouse SW; Fink C; Frey A; Moreyra E; Traboulsi M; Racine N; Riba AL; Thompson MA; Rohrbeck S; Lundergan CF
J Am Coll Cardiol; 1999 Dec; 34(7):1954-62. PubMed ID: 10588209
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcome of patients in whom reperfusion with intravenous tissue-type plasminogen activator fails: results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) I trial.
Califf RM; Topol EJ; George BS; Boswick JM; Lee KL; Stump D; Dillon J; Abbottsmith C; Candela RJ; Kereiakes DJ
Circulation; 1988 May; 77(5):1090-9. PubMed ID: 2966016
[TBL] [Abstract][Full Text] [Related]
6. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
Arnold AE; Simoons ML; Van de Werf F; de Bono DP; Lubsen J; Tijssen JG; Serruys PW; Verstraete M
Circulation; 1992 Jul; 86(1):111-20. PubMed ID: 1617763
[TBL] [Abstract][Full Text] [Related]
7. Comparison of immediate invasive, delayed invasive, and conservative strategies after tissue-type plasminogen activator. Results of the Thrombolysis in Myocardial Infarction (TIMI) Phase II-A trial.
Rogers WJ; Baim DS; Gore JM; Brown BG; Roberts R; Williams DO; Chesebro JH; Babb JD; Sheehan FH; Wackers FJ
Circulation; 1990 May; 81(5):1457-76. PubMed ID: 2110033
[TBL] [Abstract][Full Text] [Related]
8. Thrombolysis and percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction.
Zeymer U; Neuhaus KL
Z Kardiol; 2000; 89 Suppl 4():IV30-40. PubMed ID: 10810775
[TBL] [Abstract][Full Text] [Related]
9. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. The TIMI Research Group.
JAMA; 1988 Nov; 260(19):2849-58. PubMed ID: 2972848
[TBL] [Abstract][Full Text] [Related]
10. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the Combined Abciximab REteplase Stent Study in Acute Myocardial Infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial.
Di Mario C; Dudek D; Piscione F; Mielecki W; Savonitto S; Murena E; Dimopoulos K; Manari A; Gaspardone A; Ochala A; Zmudka K; Bolognese L; Steg PG; Flather M;
Lancet; 2008 Feb; 371(9612):559-68. PubMed ID: 18280326
[TBL] [Abstract][Full Text] [Related]
11. [Advantages of immediate coronary dilatation after thrombolysis using tissue-type plasminogen activator in acute myocardial infarction. A European Cooperative Group trial].
Vahanian A
Arch Mal Coeur Vaiss; 1988 May; 81 Spec No():39-43. PubMed ID: 2973300
[TBL] [Abstract][Full Text] [Related]
12. The European Cooperative Study Group trial of intravenous recombinant tissue-type plasminogen activator (rt-PA) and conservative therapy versus rt-PA and immediate coronary angioplasty.
de Bono DP
J Am Coll Cardiol; 1988 Dec; 12(6 Suppl A):20A-23A. PubMed ID: 2973485
[TBL] [Abstract][Full Text] [Related]
13. Does antithrombotic therapy influence residual thrombus after thrombolysis of platelet-rich thrombus? Effects of recombinant hirudin, heparin, or aspirin.
Mruk JS; Zoldhelyi P; Webster MW; Heras M; Grill DE; Holmes DR; Fuster V; Chesebro JH
Circulation; 1996 Feb; 93(4):792-9. PubMed ID: 8641009
[TBL] [Abstract][Full Text] [Related]
14. A pilot trial of recombinant desulfatohirudin compared with heparin in conjunction with tissue-type plasminogen activator and aspirin for acute myocardial infarction: results of the Thrombolysis in Myocardial Infarction (TIMI) 5 trial.
Cannon CP; McCabe CH; Henry TD; Schweiger MJ; Gibson RS; Mueller HS; Becker RC; Kleiman NS; Haugland JM; Anderson JL
J Am Coll Cardiol; 1994 Apr; 23(5):993-1003. PubMed ID: 8144799
[TBL] [Abstract][Full Text] [Related]
15. Ridogrel as an adjunct to thrombolysis in acute myocardial infarction.
van der Wieken LR; Simoons ML; Laarman GJ; Van den Brand M; Nijssen KM; Dellborg M; Hermens W; Vrolik W
Int J Cardiol; 1995 Nov; 52(2):125-34. PubMed ID: 8749872
[TBL] [Abstract][Full Text] [Related]
16. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.
Topol EJ; Califf RM; George BS; Kereiakes DJ; Abbottsmith CW; Candela RJ; Lee KL; Pitt B; Stack RS; O'Neill WW
N Engl J Med; 1987 Sep; 317(10):581-8. PubMed ID: 2956516
[TBL] [Abstract][Full Text] [Related]
17. [Usefulness of combination therapy of hybrid thrombolysis followed by back-up percutaneous transluminal coronary angioplasty in patients with acute myocardial infarction].
Mukawa H; Sone T; Tsuboi H; Kondo J; Kosokabe T; Uesugi M; Imai H
J Cardiol; 2001 Apr; 37(4):181-9. PubMed ID: 11337927
[TBL] [Abstract][Full Text] [Related]
18. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. Heparin-Aspirin Reperfusion Trial (HART) Investigators.
Hsia J; Hamilton WP; Kleiman N; Roberts R; Chaitman BR; Ross AM
N Engl J Med; 1990 Nov; 323(21):1433-7. PubMed ID: 2122251
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of late potentials after myocardial infarction treated with systemic thrombolysis or primary percutaneous transluminal coronary angioplasty.
Bruna C; Rossetti G; Vado A; Racca E; Steffenino G; Dellavalle A; Ribichini F; Ferrero V; Menardi E; Uslenghi E
G Ital Cardiol; 1998 Jan; 28(1):3-11. PubMed ID: 9493040
[TBL] [Abstract][Full Text] [Related]
20. Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK).
Neuhaus KL; von Essen R; Vogt A; Tebbe U; Rustige J; Wagner HJ; Appel KF; Stienen U; König R; Meyer-Sabellek W
J Am Coll Cardiol; 1994 Jul; 24(1):55-60. PubMed ID: 8006283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
